Sarcopenia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4517521
  • Report
  • 81 pages
  • P&S Market Research
1 of 3
The study analyzed that the sarcopenia therapeutics pipeline comprises of 13 drug candidates in different stages of development. Further, the analysis also states that the pipeline has around 15% of the drug candidates that are being developed as gene therapy.

Insights on Pipeline Segments

Novartis AG, and Regeneron Pharmaceuticals Inc., have one drug candidate each in the Phase II stage of development for the treatment of the disease. In December 2017, Biophytis SAS announced that the Federal Agency for Medicines and Health Products (FAMHP) approved to conduct the SARA-INT Phase II interventional study of sarcopenia in Belgium.

Sarcopenia therapeutics Pipeline Marked by Positive Clinical Trials Results

The drugs being developed by the various pharmaceutical companies for the treatment of sarcopenia have demonstrated positive clinical trial results which in-turn aids in their further development. For instance, In June 2017, Novartis AG announced the positive results of a 24-week randomized, double-blind, placebo-controlled, parallel-arm, proof-of-concept study of bimagrumab on skeletal muscle mass and function in older adults with sarcopenia and mobility limitations. In February 2016, ATA 842 demonstrated increased muscle mass and muscle strength in the treatment of young and old mice in four weeks.

Rise in Patent Approvals for Sarcopenia Therapeutics Expected to Provide Collaborative Opportunities to the Pharmaceutical Companies

It has been observed that most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of sarcopenia. For instance, in June 2016, Novartis AG received patent for the invention related to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of age-related sarcopenia (WO2015IB59369 20151204). Patent approval helps in increasing opportunities for invention improvement and uniqueness for the pharmaceutical companies.

Some of the key players developing drugs for the treatment of sarcopenia include Novartis AG, Biophytis SAS and Vibe Pharmaceuticals LLC.
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents by industry participant by company type

3. Executive Summary

4. Pipeline Outlook
4.1 Disease Overview
4.2 Sign & Symptoms
4.3 Epidemiology
4.4 Pathophysiology
4.5 Diagnosis
4.6 Prevention and Treatment
4.7 Key Drivers
4.7.1 Technological Advancements
4.7.2 Increased Funding from Government Bodies and Private Sector
4.8 Key Barriers
4.8.1 Safety Concerns
4.9 Sarcopenia Therapeutics Pipeline Analysis
4.9.1 Pipeline Analysis by Phase
4.9.2 Pipeline Analysis by Molecule Type
4.9.3 Pipeline Analysis by Route of Administration
4.9.4 Pipeline Analysis by Company

5. Sarcopenia Therapeutics Pipeline Analysis by Phase (2018)
5.1 Phase II
5.1.1 Bimagrumab Pre-Clinical trial results Clinical trials Clinical trials results Strategic development
5.1.2 X Clinical trials
5.2 Phase I
5.2.1 Sarcone Pre-Clinical results Clinical trials Clinical trial results Strategic development Technology
5.2.2 X Strategic development Technology
5.3 Pre-Clinical
5.3.1 Enzyme/Protein Replacement Therapy for Sarcopenia - Immusoft Corporation Technology Strategic development
5.3.2 X Pre-Clinical studies Strategic development
5.3.3 X Technology Strategic development
5.3.4 X Pre-Clinical results Strategic development
5.4 Discovery
5.4.1 VB-102 Technology
5.4.2 X Strategic developments Technology
5.4.3 X
5.4.4 X
5.5 Unknown
5.5.1 X Technology

6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status

7. Competitive Landscape
7.1 Key Players Benchmarking for Sarcopenia Therapeutics Pipeline
7.2 SWOT Analysis of Sarcopenia Therapeutics Pipeline

8. Company Profiles
8.1 Biophytis SAS
8.1.1 Business Overview
8.1.2 Products and Service Offerings
8.2 Vibe Pharmaceuticals LLC
8.2.1 Business Overview
8.2.2 Products and Service Offerings
8.3 Neurotune AG
8.3.1 Business Overview
8.3.2 Products and Service Offerings
8.4 X
8.4.1 Business Overview
8.4.2 Products and Service Offerings
8.5 X
8.5.1 Business Overview
8.5.2 Products and Service Offerings
8.6 X
8.6.1 Business Overview
8.6.2 Product and Service Offerings
8.7 Novartis AG
8.7.1 Business Overview
8.7.2 Product and Service Offerings
8.8 X
8.8.1 Business Overview
8.8.2 Product and Service Offerings
8.9 X
8.9.1 Business Overview
8.9.2 Products and Service Offerings
8.10 X
8.10.1 Business Overview
8.10.2 Product and Service Offerings

9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Table 1 Pipeline Analysis of Sarcopenia Therapeutics, by Company (2018)
Table 2 Description of Bimagrumab
Table 3 Clinical Trials of Bimagrumab
Table 4 Description of X
Table 5 Description of Sarcone
Table 6 Description of X
Table 7 Description of Enzyme/Protein Replacement Therapy For Sarcopenia - Immusoft Corporation
Table 8 Description of X
Table 9 Description of X
Table 10 Description of X
Table 11 Description of Vb-102
Table 12 Description of X
Table 13 Description of X
Table 14 Description of X
Table 15 Description of X
Table 16 Biophytis Sas - At a Glance
Table 17 Vibe Pharmaceuticals Llc - At a Glance
Table 18 X- At a Glance
Table 19 X- At a Glance
Table 20 X- At a Glance
Table 21 X- At a Glance
Table 22 Novartis Ag - At a Glance
Table 23 X- At a Glance
Table 24 X- At a Glance
Table 25 X - At a Glance

List of Figures
Fig 1: Research Methodology
Fig 2: Breakdown of Primary Research Respondents, by Industry Participant
Fig 3: Breakdown of Primary Research Respondents, by Company Type
Fig 4: Sarcopenia Drug Candidates In Development (2018)
Fig 5: Sarcopenia Pipeline Split, by Molecule Type (2018)
Fig 6: Sarcopenia Pipeline Split, by Route of Administration (2018)
Fig 7: Breakdown of Clinical Trials, by Region
Fig 8: Breakdown of Clinical Trials, by Trial Status
Fig 9: Key Players Benchmarking
Fig 10: SWOT Analysis
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown